methyl 2-(cis-3-hydroxycyclohexyloxymethyl)-6-methylbenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(cis-3-hydroxycyclohexyloxymethyl)-6-methylbenzoate
• 英文别名: methyl cis-2-(3-hydroxycyclohexyloxymethyl)-6-methylbenzoate；methyl 2-(3-hydroxycyclohexyloxymethyl)-6-methylbenzoate；methyl 2-[(3-hydroxycyclohexyl)oxymethyl]-6-methylbenzoate
• 化学式: C₁₆H₂₂O₄
• 分子量: 278.348
• InChiKey: WIONSNLWNWJORQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(cis-3-hydroxycyclohexyloxymethyl)-6-methylbenzoate 在 Candida antartika lipase B 作用下， 以 乙酸乙烯酯 为溶剂， 反应 7.0h， 生成 methyl (1R,3S)-2-(3-hydroxycyclohexyloxymethyl)-6-methylbenzoate
  参考文献：
  名称：

  Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals

  摘要：

  日记环烷基衍生物，其制备方法及其作为药物的用途。该发明涉及日记环烷基衍生物及其生理上可接受的盐、消旋体和生理功能衍生物。所描述的化合物为式I的化合物，其中基团如所定义，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗相关的疾病。

  公开号：

  US20040204462A1
• 作为产物：
  描述：

  1,3-环己二醇 、 2-bromomethyl-6-methyl-benzoic acid methyl ester 在 二正丁基氧化锡 、 cesium fluoride 作用下， 以 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 methyl 2-(cis-3-hydroxycyclohexyloxymethyl)-6-methylbenzoate
  参考文献：
  名称：

  Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  公开了二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。这些化合物包括式I的那些，其中基团如所定义的，并公开了它们的生理上可接受的盐和制备过程。这些化合物通常具有降脂和/或三酸甘油酯降低性，并且适用于治疗脂质代谢紊乱、II型糖尿病和X综合征等疾病。

  公开号：

  US20050267177A1

文献信息

• Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209873A1

  公开（公告）日：2004-10-21

  Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl derivatives having branched side chains and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  含有分支侧链的芳基环烷衍生物、其制备方法以及作为药物的用途。该发明涉及具有分支侧链的芳基环烷衍生物及其生理上可接受的盐和生理功能衍生物。描述的是符合以下公式I的化合物，其中基团如定义所示，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱、葡萄糖利用紊乱以及胰岛素抵抗相关疾病。
• Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209931A1

  公开（公告）日：2004-10-21

  Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives A process is described for preparing chiral, nonracemic, cis-configured 1,3-disubstituted cyclohexanols of the formula (I) 1 where the radicals are as defined, by means of enzymatic optical resolution.

  描述了一种用于制备手性、非对映体、顺式配置的1,3-二取代环己醇衍生物的过程，其化学式为(I)，其中基团如所定义，通过酶促光学分辨的方法。
• Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
  申请人：——

  公开号：US20030144332A1

  公开（公告）日：2003-07-31

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披萨店的员工们正在忙着准备今晚的外卖订单。
• Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07399777B2

  公开（公告）日：2008-07-15

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  本文披露了二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。其中化合物包括公式I中的基团，其定义如下，并且还包括它们的生理上可接受的盐和制备它们的过程。这些化合物通常具有降脂和/或降三酰甘油的特性，例如适用于治疗脂质代谢紊乱、II型糖尿病和X综合征等疾病。
• DIARYLCYCLOALKYLDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1599454B1

  公开（公告）日：2012-12-26